Background: Obstructive sleep apnea hypopnea syndrome (OSAHS) is closely correlated to obesity and T2DM. Lose weight is helpful for OSAHS patients. Dapagliflozin, a new hypoglycemic drug, was found to reduce weight of T2DM patients, just like metformin. Therefore, they might have potential therapeutic effects on OSAHS patients with T2DM. Aim: A randomized controlled trial was designed to observe the effects of dapagliflozin combined with metformin on body mass index (BMI), and the ventilation and sleep quality of patients with OSAHS combined with T2DM, as well as some metabolic indicators.
Methods: 36 enrolled OSAHS patients with newly-diagnosed T2DM were randomly assigned to two groups (dapagliflozin group and control group). These patients in dapagliflozin group were given dapagliflozin and metformin for 24 weeks, while controls were given glimepiride and metformin for 24 weeks. apnea-hypopnea index (AHI), minimum oxygen saturation (LSpO2), Epworth somnolence scale (ESS) score and some metabolic indicators were measured before and at 24 weeks after the initiation of treatment.
Results and Conclusion: Our study indicate that dapagliflozin can significantly reduce glucose, BMI, blood pressure and AHI, and improve hypoxemia during sleep and excessive daytime sleepiness (Table 1), which thereby has potential as an effective treatment approach for OSAHS.
Q. Sun: None. Y. Tang: None. M. Zhang: None.